A Look into Psoriasis Drugs Industry……Deep Analysis…..


The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, as per a new report by Grand View Research, Inc., experiencing a CAGR of 9.4% during the forecast period. Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.
Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.
Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.
To Request Sample Copy of this report, click the link:
https://www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market/request/rs1
Further key findings from the report suggest:
·         Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing to its higher usage by healthcare practitioners and easy availability
·         TNF-inhibitors are likely to lose market shares over the forecast period due to increasing preference for IL-inhibitor therapy to conventional TNF-inhibitors
·         Interleukin-inhibitors is expected to register a lucrative CAGR of over 21.0% during the forecast period owing to improved safety and efficacy profiles of Interleukin-inhibiting drugs
·         The U.S is the dominant region in the psoriasis market in terms of revenue in 2016 due to increasing number of patients seeking treatment and presence of well-established healthcare services
·         Japan is expected to be the fastest growing region during the same period due to growing awareness about the disease among the populace
·         Some of the key players in this industry are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck.
The global psoriasis drugs market size was valued at USD 11.3 billion in 2016. It is anticipated to post a CAGR of 9.4% during the forecast period. Increasing awareness regarding treatment and rising demand for improved healthcare infrastructure are among the primary growth stimulants for the market.
Psoriasis is a genetic condition that may not be present at birth. The condition may be triggered by certain environmental and genetic factors. Changing lifestyles of people are leading to increased alcohol consumption and smoking, unhealthy diet, and sedentary living, which makes people more prone to this condition.
Findings of the International Federation of Psoriasis Association indicate that about 5.0% people suffer from one or more forms of psoriasis across the globe. Nearly 7.5 million people are affected by this condition in the U.S. alone. These patients represent approximately 2.0% of the population. Moreover, approximately 100,000 new cases are registered and reported every year.
Plaque psoriasis is the leading one among the different forms, with more than four fifth of total patient base suffering at a global level. Guttate psoriasis is the second most prevalent form, affecting approximately 10.0% of patients. Erythrodermic psoriasis is the rarest but the most dangerous type. This condition demands a medical emergency, often leading to hospitalization of patients.
The market has been divided into tumor necrosis factor (TNF)-inhibitors, interleukin inhibitors, and others. TNF inhibitors were the leading therapeutic class in the psoriasis drugs market in 2016. However, they are likely to lose shares over the forecast. The marketed TNF-inhibitors used for psoriasis are Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), and Cimzia (cetolizumab pegol).
Interleukin (IL) inhibitors are expected to witness the fastest growth over the forecast period due to their improved safety and efficacy profiles and rising adoption among end users. Cosentyx (secukinumab), Taltz (ixekizumab), Stelara (ustekinumab), Siliq (brodalumab), Tremfya (guselkumab), and Ilumya (tildrakizumab) are approved as interleukin inhibitors for psoriasis.
Browse Press Release of this report:
https://www.grandviewresearch.com/press-release/global-psoriasis-drugs-market
Grand View Research has segmented the global psoriasis drugs market based on therapeutic class, treatment, and region:
Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)
·         Tumor Necrosis Factor Inhibitor
·         Interleukin Inhibitors
·         Others
Treatment Outlook (Revenue, USD Million, 2016 - 2022)
·         Topicals
·         Systemic
·         Biologics
Regional Outlook (Revenue, USD Million, 2016 - 2022)
·         U.S.
·         U.K.
·         Germany
·         Spain
·         France
·         Italy
·         Japan
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.





Comments

Post a Comment

Popular posts from this blog

Foot Orthotic Insoles Market 2026: What Will Be Changes In Investment Ratio With Opportunity Analysis?? |Grand View Research, Inc.

Image
The global foot orthotic insoles market size is expected to reach USD 5.5 billion by 2026 , according to a new report by Grand View Research, Inc., exhibiting a 6.3% CAGR during the forecast period. Growing incidence of diabetes and plantar fasciitis are expected to drive the market over the forecast period. Moreover, rapid urbanization and increasing disposable income are anticipated to propel growth in future. Technological advancements, spurred by ongoing investments in R&D, are expected to increase growth potential in the coming years. Moreover, rise in geriatric population, which is susceptible to orthopedic disorders, is impelling product demand globally. For instance, in 2017 as per the U.S. Census Bureau, the number of people aged 65 or older increased by 1.6 million from 2014 to 2015. In addition, increasing incidence of sports injuries and rising prevalence of osteosarcoma in the region has led to the need for various orthotics devices, which is expected to drive ...
Read more

A Look into Smokehouse Industry……Deep Analysis…..

Image
The global smokehouse market size is anticipated to reach USD 157.2 million by 2025 , according to a new report by Grand View Research, Inc. The market is anticipated to register a CAGR of 2.2% during the forecast period. Rising need for a healthy lifestyle has led consumers to prefer griller or barbequed food over fried food and other kinds of fast food. This trend is expected to have a positive impact on the market growth. The home care & decor industry has been witnessing inconsistent growth, since the Covid 19 outbreak. As a result of the ongoing pandemic crisis, there has been a drop in the overall performance of discretionary products such as decorative fixtures, bedding products, to name a few. The virus outbreak has, however, led to substantial growth in categories such as cleaning and hygiene products. Prominent growth in the e-commerce business is also one of the positive influences of the outbreak, wherein companies are focusing on expanding their distribution ...
Read more

A Look into Shapewear Industry……Deep Analysis…..

Image
The global shapewear market size is expected to reach USD 3.80 billion by 2025 registering a CAGR of 7.7%, according to a new report by Grand View Research, Inc. The introduction of various products according to the type of garments is expected to support the market growth in the years to come. Growing target population across the globe is also augmenting the market growth. Changing lifestyle incurs increased investment in fitness and related accessories, which has positively impacted the market growth. The clothing, footwear, & accessories industry is anticipated to witness checkered growth throughout 2020, as a result of the unprecedented supply chain disruptions caused by the COVID-19 outbreak worldwide. The expected decline in the global sales of clothing, footwear, & accessories is attributable to massive supply chain disruptions across significant export markets, including China and India. However, the industry is likely to recover over the forecast timeframe,...
Read more